{"protocolSection":{"identificationModule":{"nctId":"NCT06481956","orgStudyIdInfo":{"id":"[2023]-06-10"},"organization":{"fullName":"Zhejiang Cancer Hospital","class":"OTHER"},"briefTitle":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","officialTitle":"Phase II Clinical Study of Trastuzumab Emtansine (T-DM1) Combined With Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Ribociclib in the Treatment of Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Advanced Breast Cancer"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"ENROLLING_BY_INVITATION","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-10-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Zheng Yabing","investigatorTitle":"Deputy director","investigatorAffiliation":"Zhejiang Cancer Hospital"},"leadSponsor":{"name":"Zheng Yabing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer.","detailedDescription":"This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety of Trastuzumab Emtansine (T-DM1) combined with CDK4/6 inhibitor Ribociclib in the treatment of unresectable locally advanced or metastatic HER2-positive breast cancer."},"conditionsModule":{"conditions":["HER2-positive Advanced Breast Cancer"],"keywords":["HER2-positive","Advanced breast cancer","Trastuzumab Emtansine","Ribociclib"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"T-DM1 combined with Ribociclib","type":"EXPERIMENTAL","description":"Enrolled patients will receive (repeat every 21 days) :\n\n● T-DM1 3.6 mg/kg d1;● Ribociclib 400 mg qd, d8-d21;\n\n\\* ER-positive patients will receive endocrine therapy at the same time: aromatase inhibitors or fulvestrant , and ovarian suppression or ovariectomy in premenopausal women.","interventionNames":["Drug: Ribociclib Oral Tablet"]}],"interventions":[{"type":"DRUG","name":"Ribociclib Oral Tablet","description":"Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.","armGroupLabels":["T-DM1 combined with Ribociclib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"ORR is defined as the percentage of patients who achieved a best overall response of Complete Response (CR) or Partial Response (PR), per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions as assessed by the Investigator: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"up to 54 months"}],"secondaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"From date of first dose until the date of first documented progression or date of death from any cause, whichever came first.","timeFrame":"up to 54 months"},{"measure":"2-year Overall Survival (OS)","description":"the overall survival rate in all patients from the date of first dose to the end of follow-up at 2 years.","timeFrame":"up to 54 months"},{"measure":"Objective Response Rate of Subgroup Population (ORR)","description":"Objective Response Rate of subgroup population (ER\\>=10% vs ER\\<10%)","timeFrame":"up to 54 months"},{"measure":"Adverse Event (AE)","description":"Evaluation performed using the National Cancer Institute (NCI)- Standard for Common Terminology for Adverse Events (CTCAE)v.5.0.","timeFrame":"up to 54 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 at the time of signing the informed consent.\n* Patient's ability to follow the study protocol as determined by the investigator.\n* A representative tumor tissue sample is required to confirm a HER2-positive diagnosis.\n\nHER2 expression status and ER expression status of invasive cancer lesions were determined based on previous pathological sections or current pre-treatment biopsy materials, and the HER2 IHC assay was locally confirmed to be consistent with 3+, or IHC assay with 2+, and further FISH detection was positive before study enrollment.\n\n* At least one evaluable lesion was detected by CT or MRI (see protocol for additional details).\n* For metastatic or recurrent breast cancer, there is currently no opportunity for surgical radical resection.\n* Metastatic or recurrent breast cancer that has received at least first-line rescue therapy in the past must have been treated with trastuzumab and taxanes.\n* The Physical status (ECOG) score of the Eastern Tumor Collaboration group was 0 or 1.\n* Sufficient haematology and organ function to meet the definition of laboratory test results, which must be provided within 14 days before the start of study therapy.\n* Fertile women should remain abstinent (no heterosexual intercourse) or use contraceptive methods.\n\nExclusion Criteria:\n\n* Past treatment with other antibody-drug conjugate (ADC) drugs or anti-tumor therapy with CDK4/6 inhibitors.\n* Past treatment with other anti-HER2 drugs other than trastuzumab, pertuzumab and tyrosine kinase inhibitors (TKI).\n* Advanced breast cancer with central nervous system metastasis.\n* Patients who have developed other malignancies in the 5 years prior to screening, except adequately treated cervical cancer in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.\n* Severe dysfunction of vital organs prior to enrollment (see protocol details).\n* Received an investigational drug within 28 days prior to initiation of study therapy.\n* Known hypersensitivity or hypersensitivity to CDK4/6 inhibitors.\n* The results of the serum pregnancy test were positive.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yabing Zheng, MD","affiliation":"Zhejiang Cancer Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000001941","term":"Breast Diseases"},{"id":"D000012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Cancer","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"},{"id":"T4025","name":"Myotonic Dystrophy Type 1","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M325","name":"Trastuzumab","relevance":"LOW"},{"id":"M11900","name":"Mitogens","relevance":"LOW"},{"id":"M1723","name":"Fulvestrant","relevance":"LOW"},{"id":"M25769","name":"Aromatase Inhibitors","relevance":"LOW"},{"id":"M2102","name":"Ado-Trastuzumab Emtansine","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}